Ligand Pharmaceuticals, Inc.

Other

Wyeth

Nucorion Pharmaceuticals, Inc.

Smithkline Beecham Corporation

Lin Zhi

Todd Kevin Jones

Christopher Michael Tegley

James Patrick Edwards

Jay Edward Wrobel

Andrew Fensome

Puwen Zhang

Cornelis Arjan Van Oeveren

Eugene Anthony Terefenko

Bijan Pedram

Yixing Shen

Mark A Collins

Gary Sondermann Grubb

Jason Conrad Pickens

John W Ullrich

Sarah J West

David T Winn

Robert Higuchi

Andrew Richard Hudson

Lino J Valdez

Lori L Miller

Reinhold H W Bender

Steven L Roach

Valerie A Mackner

Lawrence G Hamann

Luc J Farmer

Horace Fletcher, Iii

Edward George Melenski

Keith B Marschke

Marci C Koko

Donald Karanewsky

Koc-Kan Ho

Arthur Attilio Santilli

Brian F McGuinness

Jeffrey John Letourneau

David J Diller

Andrew Graham Cole

Andrew Q Viet

David Rosen

Mark E Goldman

Virginia H Grant

Jyun-Hung Chen

Robert L Davis

Thomas Lot Stevens Lau

Dean Paul Phillips

Mark E Adams

Andrew G Cole

Charlotte Lf Pooley

Esther Martinborough

Marcus F Boehm

Barbara A Pio

Richard Alan Heyman

Jillian Basinger

E Adam Kallel

Todd Anthony Miller

Alex M Nadzan

Virginia Heather Sharron Grant

Thomas Lau

Jackline Eve Dalgard

Matthew McNeill

Reinhold R W Bender

Steve White

Shuo Zhao

Daniel A Ruppar

Thomas R Caferro

Neelakandha S Mani

Bao Vinh Nguyen

Yun Long

Yan Liu

Chan Kou Hwang

Bao Ngoc Nguyen

Martin Osterhout

Min Wu

Richard Julius Penuliar

Ian Henderson

Kristen Lee Arienti

Anthony W Thompson

Charlotte L F Pooley

Catalina Cuervo

Virgina H Grant

Chan Kou (Jack) Hwang

Mehrnouch Motamedi

Penghui Chen

Mani Neelakandha

Stacie Canan Koch

Cornelius Arjan Van Oeveren

Joseph Kaloko

Richard J Penulian

Henri Sasmor

C Arjan Van Oeveren

K Raja Reddy

Marquis L Cummings

Charlotte L F Deckhut

Reinhold Hw Bender

Robert I Higuchi

Matthew H McNeill

Jason C Pickens

Bao N Nguyen

Disclosed herein are methods of crystallizing the compound of Formula (I), as well as crystalline forms thereof. Crystalline forms of Formula (I) disclosed include crystalline Form C, crystalline Form E, and Crystalline form B.

Crystalline forms and methods of producing crystalline forms of a compound

Provided herein are solid state forms of compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, ameliorating, delaying the time to onset or reducing the risk for the development or progression of at least one condition, disease, or disorder for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance, hyperglycemia, ketoacidosis, or ketosis.

Glucagon receptor antagonists

Provided herein are 5-fluorouracil derived cyclic deoxyribonucleotide compounds, their preparation and their uses, such as treating liver diseases or various types of cancer.

Cyclic deoxyribonucleotide compounds

Provided herein are phosphor (n) amidatacetal and phosph (on) atacetal compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in the molecular pathways in the liver. These compounds may be effective in the treatment of hepatitis or other viral infections either alone or in combination with one or more additional therapeutic agents.

Phosphor(n)amidatacetal and phosph(on)atalcetal compounds

Disclosed herein are acetal and cyclic acetal compounds, compositions, their preparation, and their uses. Some embodiments relate to their use as liver-targeting compounds.

Acetal compounds and therapeutic uses thereof

Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using imidazole-fused heterocycle amines. Some of the disclosed embodiments include imidazo-fused heterocycle compounds useful to treat leukemia and other hematopoietic disorders.

Imidazo-fused heterocycles and uses thereof

Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.

Heterocycle amines and uses thereof

Provided herein are nucleotide prodrug compounds, their preparation and their uses, such as treating diseases or conditions of a viral infection.

Nucleotide prodrug compounds

The compounds are of the class of 5-fluorouracil derived acetal and hemiaminal ether compounds, useful in treating liver diseases and various types of cancer. The following formulas are representative of the class of compounds provided herein: 

5-fluorouracil compounds

Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.

Methods and compositions associated with the granulocyte colony-stimulating factor receptor

Provided herein are compounds, such as compounds of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions. 

Selective androgen receptor modulators (SARMs) and uses thereof

Provided herein are prodrug compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in molecular pathways in the liver.

Prodrug compounds and their uses

Provided herein are compositions and methods for the treatment of androgen and estrogen receptors mediated conditions.

Methods and compositions for modulating hormone levels

Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using imidazole-fused heterocycle amines. Some of the disclosed embodiments include imizazo-fused heterocycle compounds useful to treat leukemia and other hematopoietic disorders.

Growing community of inventors

San Diego, CA, United States of America

Lin Zhi